ÂÜÀòÂÒÂ×

Steven Axon is a seasoned executive with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as a Board Member at Complement Therapeutics and Chief Executive Officer at Glycomine Inc. since June 2022, Steven previously held the CEO position at Prothelia from September 2019 to June 2022. Prior roles include Chief Business Officer at Apellis Pharmaceuticals and various leadership positions at Merck KGaA, including Senior VP of Business Development and Head of Alliance Management. Additionally, Steven served as Director of Strategy and Business Development at Serono Pharmaceuticals and worked as a Management Consultant at Accenture. Educational credentials include an MBA from IMD, a MASc in Biomedical Engineering, and a BASc in Bio/Mechanical Engineering, all obtained from the University of Toronto.